ECT2 and hepatocellular carcinoma: The same tumor, hepatocellular carcinoma, was promoted for recurrence also by the action of ECT2 [74] and, along with NEK2 and DLGAP5, ECT2 was identified via a genome-scale analysis to act as a prognostic biomarker in lung cancer [75].